PD-1

New research in mice reveals why natural killer cells, normally effective at hunting cancer, are sometimes stopped in their tracks.  

The results from two Phase 1 trials bolster the case that the gut microbiome plays a role in response to the drugs.

At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system’s antitumor response.

Researchers describe ways to study how cancer cells evade therapies that harness the immune system.

Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.

A case study of two patients with advanced cancer shows it might be possible to avoid a common and severe side effect of immunotherapy treatment.

Checkpoint inhibition combined with chemotherapy gives patients with triple-negative metastatic breast cancer about two months more time without significant tumor growth, a study finds.

The immunologists, honored with the 2018 award in Physiology or Medicine, pioneered immunotherapy, which harnesses the body’s immune system to fight cancer.

The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.

Pembrolizumab combined with chemotherapy nearly doubles survival rates and shrinks tumors in some individuals.

The discovery suggests that the immune checkpoint can operate at a further distance from tumor cells than previously believed.

Boosting levels of a the immunosuppressive protein PD-L1 in blood stem cells halts diabetes in a mouse model of the disease.

In mice, the tumor cells are able to thwart the immune response that would kill them—but immunotherapy prevented the return of melanoma.

A drug that blocks an immune checkpoint protein effectively treats tumors in patients with deficient DNA repair genes.